CYPLASIN BIOMEDICAL

The Company’s management team, advisors and consultants possess a deep knowledge of the Company’s products and indications, and strong start-up company management experience.

	Founder and Chairman of the Board of Directors, Dr. Joseph Sinkule is a serial entrepreneur and a 28-year biotech veteran with extensive biotech startup experience. Joe has taken several drug and recombinant protein products from discovery thru FDA approval and licensure. He was previously Sr. VP of R&D at a NASDAQ-listed biotech company and Director of Clinical Research at Immunex. Joe founded five other biotech companies and two CROs, and currently serves on the Boards of four healthcare companies.

	Chief Executive Officer and Director, Garth Likes is the founder and CEO of Cyplasin Biomedical,and served as CEO and Board member of several public companies. Garth has the industry experience to successfully navigate the Company through financings, corporate operations, and overall management of this public company entity. Because of his prior business development experience, Garth will work with Seth Goldblum to manage the corporate partnering and corporate management activities.

	Chief Business Officer, Seth Goldblum, MBA, is a biotech executive with 20 years of business development deal-making, finance and corporate management experience, particularly in the vaccine area. Seth and Garth will be a key contributors in the finance and corporate partnering areas. Seth will begin structuring the deal for out-licensing the preventive indication of the HCV vaccine to a major vaccine company.

	Chief Medical Officer and physician William Gannon M.D., MBA will manage the day-to-day activities of outsourcing and overseeing product development and the contractual arrangements with CROs, CSOs, and CMOs required to make, test, and obtain regulatory approvals of our product candidates.

The Company has begun recruiting additional staff including project management and administrative accounting positions, and is assembling a first-rate team of experienced biotech personnel that are readied for successful execution of the product development programs.

The Scientific Advisory Board of Cyplasin Biomedical will be assembled by Dr. Liang, one of world’s top experts on HCV infection and head of the Liver Disease Section of the NIH. Dr. Liang is the co-inventor of the Company's patented HCV VLP vaccine technology. Top-notched scientific expertise recruited to the SAB will help guide our direction by proving valuable technical and clinical input.

An industry-experienced Board of Directors from around the country will be recruited over the next 3-6 months to advise the management team and represent the shareholders of the Company. The Board will be comprised predominantly of independent experts contributing various expertise and insight as to overall management and value creation for the Company.

The Company is a Nevada corporation and will continue to be headquartered in Edmonton, Alberta Canada [Suite 131, Advanced Technology Center, 9650 20th Avenue, Edmonton, Alberta CANADA].